Cytokine Storm Syndrome Responsive to IL-1 Inhibition in Trisomy 21

Figure 1

Inflammatory response during anti-IL-1 therapy. Daily monitoring of blood cell counts (absolute lymphocyte counts (ALC) and platelets), serum c-reactive protein (CRP), ferritin, and liver transaminases (AST and ALT) showed rapid improvement after therapy with methylprednisolone (MP) and intravenous anakinra (in grey shade) was initiated. Anemia and marked elevations of B-type natriuretic (BNP) and soluble IL-2 (sIL-2) also reverted with therapy (data not shown).